DexCom, Inc. (DXCM)
Dexcom Stock Plummets on Earnings Miss, Guidance Cut
Shares of Dexcom (DXCM) tumbled over 40% in extended trading Thursday after the company reported second-quarter earnings that missed estimates and slashed its full-year revenue guidance.
Dexcom shares plummet 30% after company lowers fiscal year guidance
Dexcom shares plummet 30% after company lowers fiscal year guidance
CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings
DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 Healthcare Stocks to Buy at a Discount
Investors are showing varying degrees of appetite for the telehealth and diabetes care industries. Teladoc has undergone major changes in recent years, and investors are warily eyeing its path forward.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
2 Top Growth Stocks to Buy With $1,000
E-commerce powerhouse Shopify has a solid moat and plenty of room to run. DexCom's massive addressable market bodes well for its long-term prospects.
DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing on OTC CGM products like Stelo to expand target market and drive sales. Despite slight downgrade in outlook for FY24, DexCom's stock positioned for robust sales ramp in second half of the year, with potential for +20% upside.
Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034
If you are looking for millionaire-maker stocks to turn a $50,000 portfolio into $1 million in just a decade, I would like to remind you of several things. First, your portfolio would need to compound at around 35% annually.
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
The 3 Best Diabetes Stocks to Buy in June 2024
Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That's because Dexcom (NASDAQ: DXCM ) delivered stronger-than-expected third-quarter results in October.
